Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gilead SciencesFRA:GIS +2.07%74 Debt-to-Equity is 2.22 as of Jun. 2026, which is 75% above its 10-year median of 1.27. GuruFocus rates FRA:GIS with a GF Score™ of 74/100 and a GF Value™ of €91.79 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 811 Drug Manufacturers companies, Gilead Sciences ranks worse than 96.18% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Gilead Sciences's Debt-to-Equity or its related term are showing as below:
FRA:GIS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.94 Med: 1.27 Max: 2.22
Current: 2.22
During the past 13 years, the highest Debt-to-Equity Ratio of Gilead Sciences was 2.22. The lowest was 0.94. And the median was 1.27.
FRA:GIS's Debt-to-Equity is ranked worse than 96.18% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs FRA:GIS: 2.22
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Gilead Sciences Debt-to-Equity Related Terms
Gilead Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GIS vs PFE, BMY, AMGN: Debt-to-Equity Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a Debt-to-Equity of 2.22 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gilead Sciences and its competitors. This is 75% above median its historical median of 1.27. Over the past decade, Gilead Sciences' Debt-to-Equity has ranged from 0.94 to 2.22. According to the industry distribution chart, Gilead Sciences ranks #780 out of 811 companies in the Drug Manufacturers industry, placing it in the top 96.2%.
Is Gilead Sciences' Debt-to-Equity too high?
Gilead Sciences' current Debt-to-Equity of 2.22 is 75% above median its 10-year median of 1.27. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 2.22. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Gilead Sciences' value of 2.22 is 692.9% above this industry median. Based on the distribution chart, Gilead Sciences ranks #780 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gilead Sciences has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Debt-to-Equity compare to PFE and BMY?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #780 out of 811 companies for Debt-to-Equity. This places Gilead Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Gilead Sciences' value of 2.22 is 692.9% above this benchmark. Historically, Gilead Sciences' own Debt-to-Equity has ranged from 0.94 to 2.22 over the past decade. While the company's 10-year median is 1.27 vs. the industry median of 0.28, Gilead Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current Debt-to-Equity of 2.22 is 692.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current Debt-to-Equity is 2.22, which is 75% above median its own 10-year median of 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €91.79, compared to a current price of €126.12 — trading 37.4% above its estimated fair value. The current Debt-to-Equity is 2.22, which is 75% above median its 10-year median of 1.27 and 692.9% above the Drug Manufacturers industry median of 0.28. Gilead Sciences' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Debt-to-Equity is 2.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €126.12 is trading 37.4% above its estimated GF Value™ of €91.79.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
Debt-to-Equity: 2.22 (75% above median its 10-year median of 1.27)
GF Value™: €91.79 vs. price of €126.12 (37.4% above fair value)
Industry Position: 692.9% above the Drug Manufacturers median (#780 of 811)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
74GF Score
Get the complete analysis for FRA:GIS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
